piii trial supports current standard 12-month adjuvant trastuzumab for her2-positive breast cancer
Published 6 years ago • 127 plays • Length 10:05Download video MP4
Download video MP3
Similar videos
-
5:46
adjuvant trastuzumab emtansine vs paclitaxel and trastuzumab for her2-positive breast cancer
-
6:42
6 months trastuzumab non-inferior to 12 months for her2 positive early breast cancer
-
4:04
the persephone trial: 6 months and 12 months of trastuzumab in breast cancer
-
1:56
persephone: 6 vs. 12-month adjuvant trastuzumab in early breast cancer
-
6:04
katherine trial updates for her2-positive breast cancer
-
9:13
substituting trastuzumab emtansine for adjuvant trastuzumab improved idfs for breast cancer pati...
-
7:40
adjuvant trastuzumab did not improve outcomes for patients with her2-low breast cancer
-
6:47
extended adjuvant therapy for her2-positive early breast cancer
-
0:55
neoadjuvant treatment approach for her2 positive breast cancer
-
7:31
adding lapatinib to adjuvant trastuzumab doesn't improve outcomes in her2-positive breast cancer
-
3:06
trastuzumab deruxtecan effective against brain metastases in her2-positive breast cancer
-
5:29
adding lapatinib to adjuvant trastuzumab doesn't improve outcomes in her2-positive breast cancer
-
8:16
apt for her2 breast cancer patients with small tumours
-
11:04
shorther trastuzumab treatment of her2 breast cancer: 9 weeks v 1 year
-
0:46
clinical trials remain underway for trastuzumab deruxtecan in her2-positive breast cancer
-
12:27
next wave of successful drug therapy strategies in her2-positive breast cancer
-
2:01
dr. yardley on the respect trial in her2-positive breast cancer
-
1:45
dr. sramila aithal describes the herceptin adjuvant (hera) trial for her2-positive breast cancer
-
8:31
#esmo21 expert video report on her2-positive early breast cancer